The earnings call highlighted strong growth in core products and a successful acquisition, setting the stage for future growth. However, this was offset by decreased operating earnings and increased expenses. Overall, the sentiment is cautiously optimistic.

Company Guidance -

Q4 2025

In the second quarter of 2025, Supernus Pharmaceuticals reported significant developments and strong financial performance. The company launched ONAPGO, a subcutaneous apomorphine infusion device for advanced Parkinson's disease, and completed the acquisition of Sage Therapeutics. Their growth drivers, Qelbree, GOCOVRI, and ONAPGO, collectively accounted for 73% of total net sales. Qelbree prescriptions grew by 23% year-over-year, with net sales increasing by 31%. GOCOVRI saw a 14% rise in prescriptions and a 16% increase in net sales, while ONAPGO had over 750 patient enrollment forms submitted by more than 300 prescribers. The acquisition of ZURZUVAE, a product from Sage, added to their growth trajectory, with its net revenues increasing by 68% quarter-over-quarter to $23.2 million. Financially, Supernus reported total revenues of $165 million, with net product sales of $158 million. Despite a decrease in GAAP operating earnings to $12 million from $23 million the previous year, the company's cash position strengthened to approximately $523 million, enabling continued strategic growth initiatives. Updated guidance for full-year 2025 forecasts total revenues between $670 million and $700 million, with non-GAAP operating earnings expected to range from $105 million to $135 million.

Strong Launch of ONAPGO

ONAPGO, the first and only subcutaneous apomorphine infusion device for Parkinson's disease, was launched in April and exceeded expectations with more than 750 patient enrollment forms submitted by over 300 prescribers.

Acquisition of Sage Therapeutics

Supernus completed the acquisition of Sage Therapeutics on July 31, which is expected to accelerate mid- to long-term revenue growth and cash flow.

Growth of Core Products

Qelbree and GOCOVRI showed strong performance, with Qelbree prescriptions growing by 23% and net sales up by 31%. GOCOVRI saw a 14% increase in prescriptions and a 16% rise in net sales year-over-year.

Introduction of ZURZUVAE

ZURZUVAE, acquired from Sage Therapeutics, reported net revenues of $23.2 million in Q2 2025, a 68% increase from the previous quarter.

Financial Position and Guidance

Supernus ended Q2 with $523 million in cash and marketable securities, and increased its 2025 revenue guidance to $670 million to $700 million.

Supernus Pharmaceuticals (SUPN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SUPN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 03, 2026	2025 (Q4)	- / -	0.746	―	―	―
Aug 05, 2025	2025 (Q2)	0.47 / 0.91	0.771	17.77% (+0.14)	―
May 06, 2025	2025 (Q1)	0.37 / 0.44	0.46	-4.78% (-0.02)	―
Feb 25, 2025	2024 (Q4)	0.52 / 0.75	0.883	-15.52% (-0.14)	―
Nov 04, 2024	2024 (Q3)	0.44 / 1.17	-0.29	502.76% (+1.46)	―
Aug 06, 2024	2024 (Q2)	0.39 / 0.77	-0.02	3955.00% (+0.79)	―
May 08, 2024	2024 (Q1)	0.38 / 0.46	0.29	58.62% (+0.17)	―
Feb 27, 2024	2023 (Q4)	0.55 / 0.88	0.43	105.35% (+0.45)	―
Nov 08, 2023	2023 (Q3)	<0.01 / -0.29	0.03	-1066.67% (-0.32)	―
Aug 08, 2023	2023 (Q2)	0.21 / -0.02	0.546	-103.66% (-0.57)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SUPN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$37.53	$42.44	+13.08%
May 06, 2025	$32.43	$30.94	-4.59%
Feb 25, 2025	$32.81	$31.91	-2.74%
Nov 04, 2024	$34.70	$34.74	+0.12%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Supernus Pharmaceuticals (SUPN) report earnings?

Supernus Pharmaceuticals (SUPN) is schdueled to report earning on Mar 03, 2026, After Close (Confirmed).

What is Supernus Pharmaceuticals (SUPN) earnings time?

Supernus Pharmaceuticals (SUPN) earnings time is at Mar 03, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SUPN EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing